Condition: Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) · Inflammatory Bowel Syndrome · Sponsor: American Laboratory Products Company
The ALPCO Calprotectin CLIA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. The goal of the study is to generate data to support positive and negative predictive value of the ALPCO Calprotectin assay in patients with signs and symptoms of IBS or IBD.
This description comes directly from the study's public registry record.
Yomi Ojutalayo · 800-592-5726 · clinops@alpco.com
Jim Richard · 800-592-5726 · regulatory@alpco.com
Always discuss trial participation with your own doctor first.
| Med-Care Research Corp | Miami, Florida, United States | Recruiting |
| ALPCO | Salem, New Hampshire, United States | Not Yet Recruiting |
| Gastro Intestinal Research Institute of Northern Ohio, | Westlake, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06810518